Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
In spite of the success of PD-1 blocking antibodies in the clinic their benefits are still restricted to a small fraction of patients. Immune-desert tumors and/or the highly immunosuppressive tumor milieu might hamper the success of PD-1/PD-L1 blocking therapies into a broader range of cancer patien...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-08-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1450711 |
id |
doaj-a00e6e238c7a4f1aa23b2515f56475ec |
---|---|
record_format |
Article |
spelling |
doaj-a00e6e238c7a4f1aa23b2515f56475ec2020-11-25T03:18:50ZengTaylor & Francis GroupOncoImmunology2162-402X2018-08-017810.1080/2162402X.2018.14507111450711Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumorsMario M Soldevilla0Helena Villanueva1Naiara Martinez-Velez2Daniel Meraviglia-Crivelli3Marta M Alonso4Javier Cebollero5Ashwathi P Menon6Montserrat Puigdelloses7Fernando Pastor8Molecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraMolecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraInstituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de NavarraMolecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraInstituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de NavarraMolecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraMolecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraInstituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de NavarraMolecular Therapeutics Program, Center for Applied Medical Research, CIMA, University of NavarraIn spite of the success of PD-1 blocking antibodies in the clinic their benefits are still restricted to a small fraction of patients. Immune-desert tumors and/or the highly immunosuppressive tumor milieu might hamper the success of PD-1/PD-L1 blocking therapies into a broader range of cancer patients. Although still under debate, there is a cumulative body of evidence that indicates B tumor-infiltrating lymphocytes are a good prognostic marker in most types of cancer, especially in those that form ectopic lymphoid tissue structures. Taking this into account, we reason that the adoptive transfer of activated B lymphoblasts (ABL) in the tumor could be a feasible therapeutic approach to shift the immunosuppressive tumor microenvironment into an immune-permissive one. In this work we show the antitumor effect of ABL therapy in two different tumor models: colon carcinoma (CT26) and melanoma (B16/F10). The ABL transfer in the most relevant non-immunogenic B16/F10 melanoma model depicts synergism with anti-PD-1 antibody therapy. Furthermore, systemic antitumor immunity was detected in mice treated with PD-1 antibody/ABL combination which was able to reach distal metastatic lesions.http://dx.doi.org/10.1080/2162402X.2018.1450711cancer immunotherapyb lymphocytespd1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mario M Soldevilla Helena Villanueva Naiara Martinez-Velez Daniel Meraviglia-Crivelli Marta M Alonso Javier Cebollero Ashwathi P Menon Montserrat Puigdelloses Fernando Pastor |
spellingShingle |
Mario M Soldevilla Helena Villanueva Naiara Martinez-Velez Daniel Meraviglia-Crivelli Marta M Alonso Javier Cebollero Ashwathi P Menon Montserrat Puigdelloses Fernando Pastor Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors OncoImmunology cancer immunotherapy b lymphocytes pd1 |
author_facet |
Mario M Soldevilla Helena Villanueva Naiara Martinez-Velez Daniel Meraviglia-Crivelli Marta M Alonso Javier Cebollero Ashwathi P Menon Montserrat Puigdelloses Fernando Pastor |
author_sort |
Mario M Soldevilla |
title |
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
title_short |
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
title_full |
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
title_fullStr |
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
title_full_unstemmed |
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
title_sort |
intratumoral injection of activated b lymphoblast in combination with pd-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors |
publisher |
Taylor & Francis Group |
series |
OncoImmunology |
issn |
2162-402X |
publishDate |
2018-08-01 |
description |
In spite of the success of PD-1 blocking antibodies in the clinic their benefits are still restricted to a small fraction of patients. Immune-desert tumors and/or the highly immunosuppressive tumor milieu might hamper the success of PD-1/PD-L1 blocking therapies into a broader range of cancer patients. Although still under debate, there is a cumulative body of evidence that indicates B tumor-infiltrating lymphocytes are a good prognostic marker in most types of cancer, especially in those that form ectopic lymphoid tissue structures. Taking this into account, we reason that the adoptive transfer of activated B lymphoblasts (ABL) in the tumor could be a feasible therapeutic approach to shift the immunosuppressive tumor microenvironment into an immune-permissive one. In this work we show the antitumor effect of ABL therapy in two different tumor models: colon carcinoma (CT26) and melanoma (B16/F10). The ABL transfer in the most relevant non-immunogenic B16/F10 melanoma model depicts synergism with anti-PD-1 antibody therapy. Furthermore, systemic antitumor immunity was detected in mice treated with PD-1 antibody/ABL combination which was able to reach distal metastatic lesions. |
topic |
cancer immunotherapy b lymphocytes pd1 |
url |
http://dx.doi.org/10.1080/2162402X.2018.1450711 |
work_keys_str_mv |
AT mariomsoldevilla intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT helenavillanueva intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT naiaramartinezvelez intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT danielmeravigliacrivelli intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT martamalonso intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT javiercebollero intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT ashwathipmenon intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT montserratpuigdelloses intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors AT fernandopastor intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors |
_version_ |
1724625614372077568 |